Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

Tremfya (guselkumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as psoriatic arthritis. Tremfya comes as a liquid solution for injection. If you’d like ...

Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more here.

There is a notable lack of randomized controlled trials (RCTs) of quality for DMARD treatment ... Psoriatic Arthritis Clinic (ON, Canada) suggested that the larger doses of MTX used since the ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Targeted therapies for PsA are effective for reducing the use of symptomatic treatments, sick leave, and rates of hospitalization.

Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...

When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.

Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.